Geode Capital Management Increases Stake in Nuvation Bio Amid Insider Buying Geode Capital Management has raised its holdings in Nuvation Bio, while CEO David Hung recently acquired 200,000 shares, reflecting growing insider confidence. The company, focused on oncology therapeutics, now sees insiders owning over 5% of its stock. This activity comes as Nuvation advances several clinical-stage cancer drug candidates.12